stocks logo

PRAX

Praxis Precision Medicines Inc
$
48.600
+0.81(1.695%)1D
  • Overview
  • Forecast
  • Valuation
  • Earnings
Line
Line
|
Candle
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
50.335
Open
47.710
VWAP
47.68
Vol
455.35K
Mkt Cap
1.02B
Low
46.155
Amount
21.71M
EV/EBITDA(TTM)
--
Total Shares
17.11M
EV
704.50M
EV/OCF(TTM)
--
P/S(TTM)
125.26
Praxis Precision Medicines, Inc. is a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. The Company is applying genetic insights to the discovery and development of therapies for neurological disorders through two platforms, using its understanding of shared biological targets and circuits in the brain. Its platform includes Cerebrum, a small-molecule platform, which utilizes deep understanding of neuronal excitability and neuronal networks and applies a series of computational and experimental tools to develop orally available precision therapies, and Solidus, an antisense oligonucleotide platform, is an efficient, targeted precision medicine discovery and development engine anchored on a proprietary, computational methodology. The Company’s product candidates include ulixacaltamide, vormatrigine, relutrigine, PRAX-080, and others.
Show More

Market Estimates

Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q3
FY2025Q2
69.35K
-77.04%
--
--
157.13K
-55.99%
--
--
Estimates Revision
The market is revising Downward the revenue expectations for Praxis Precision Medicines, Inc. (PRAX) for FY2025, with the revenue forecasts being adjusted by -19.41% over the past three months. During the same period, the stock price has changed by 38.19%.
Revenue Estimates for FY2025
Revise Downward
down Image
-19.41%
In Past 3 Month
Stock Price
Go Up
up Image
+38.19%
In Past 3 Month
9 Analyst Rating
up Image
133.29% Upside
Wall Street analysts forecast PRAX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PRAX is 113.38 USD with a low forecast of 61.00 USD and a high forecast of 270.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
9 Buy
0 Hold
0 Sell
Strong Buy
up Image
133.29% Upside
Current: 48.600
sliders
Low
61.00
Averages
113.38
High
270.00
H.C. Wainwright
H.C. Wainwright
Buy
maintain
$105 -> $115
2025-08-05
New
Reason
H.C. Wainwright raised the firm's price target on Praxis Precision to $115 from $105 and keeps a Buy rating on the shares. The firm says the RADIANT trial data showcased vormatrigine's "best-in-disease" efficacy in highly refractory focal onset seizure.
Oppenheimer
Oppenheimer
Outperform
maintain
$97 -> $115
2025-07-08
Reason
Oppenheimer raised the firm's price target on Praxis Precision to $115 from $97 and keeps an Outperform rating on the shares. The firm sees an attractive setup for investors into Phase 2 RADIANT study of vormatrigine in epilepsy patients. Oppenheimer anticipates the readout within the next few weeks, and sees potential upside for the shares upon vormatrigine demonstrating a monthly seizure frequency reduction over 50% with favorable safety/tolerability data, considering the study design with 8-week open-label treatment, prior Phase 2 POC data supporting potential efficacy, read-through from relutrigine in DEE patients, and Phase 2 data from potential competitor drugs XEN1101 and cenobamate. The firm's scenario analysis forecasts +15% probability-adjusted upside. Oppenheimer anticipates RADIANT results to inform the design of pivotal Phase 3 POWER2 study while Phase 2/3 POWER1 continues enrolling with topline results expected in the second half of 2025.
Oppenheimer
Jay Olson
Outperform
initiated
$97
2025-06-02
Reason
Oppenheimer analyst Jay Olson assumed coverage of Praxis Precision with an Outperform rating and $97 price target following quarterly results. Given the multiple upcoming readouts across its pipeline, the firm remains encouraged by management's execution. For the vomatrigine program, Oppenheimer looks forward to the RADIANT and POWER1 registrational Phase 2/3 topline results, still expected in mid-2025 and the second half of 2025, respectively.
Needham
Ami Fadia
Strong Buy
Reiterates
$85
2025-04-08
Reason
HC Wainwright & Co.
Douglas Tsao
Strong Buy
Maintains
$120 → $105
2025-03-03
Reason
Needham
Ami Fadia
Strong Buy
Maintains
$150 → $85
2025-03-03
Reason
Needham lowered the firm's price target on Praxis Precision to $85 from $150 and keeps a Buy rating on the shares. The firm is removing Ulixa sales from its model after the company disclosed last week that Independent Data Monitoring Committee recommended that its study be stopped for futility, due to the results being unlikely to meet the primary efficacy endpoint, the analyst tells investors in a research note. At this time, the firm is assuming that the probability of success for this program is "minimal" until there is more clarity on the final topline, Needham added.

Valuation Metrics

The current forward P/E ratio for Praxis Precision Medicines Inc (PRAX.O) is -3.56, compared to its 5-year average forward P/E of -4.80. For a more detailed relative valuation and DCF analysis to assess Praxis Precision Medicines Inc 's fair value, click here.

Forward PE

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-4.80
Current PE
-3.56
Overvalued PE
-0.13
Undervalued PE
-9.46

Forward EV/EBITDA

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-3.10
Current EV/EBITDA
-2.29
Overvalued EV/EBITDA
1.02
Undervalued EV/EBITDA
-7.22

Forward PS

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
293.77
Current PS
2677.36
Overvalued PS
786.19
Undervalued PS
-198.65

Financials

Annual
Quarterly
FY2025Q2
YoY :
-100.00%
0.00
Total Revenue
FY2025Q2
YoY :
+102.91%
-76.07M
Operating Profit
FY2025Q2
YoY :
+117.67%
-71.13M
Net Income after Tax
FY2025Q2
YoY :
+90.23%
-3.31
EPS - Diluted
FY2025Q2
YoY :
+100.65%
-54.73M
Free Cash Flow
FY2025Q2
YoY :
-100.00%
N/A
Gross Profit Margin - %
FY2025Q2
YoY :
-54.18%
-2.46K
FCF Margin - %
FY2025Q2
YoY :
-100.00%
N/A
Net Margin - %

Trading Trends

Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
1.1M
USD
2
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds areSelling! The selling amount has increased 339.12% over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
348.8K
Volume
1
6-9
Months
79.4K
Volume
2
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
4
1.1M
Volume
Months
6-9
4
1.3M
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months

PRAX News & Events

Events Timeline

2025-08-04 (ET)
2025-08-04
08:34:23
Praxis Precision reports Q2 EPS ($3.31), consensus ($3.36)
select
2025-08-04
08:08:41
Praxis Precision announces topline results from Phase 2 RADIANT study
select
2025-07-17 (ET)
2025-07-17
08:03:02
Praxis Precision receives FDA Breakthrough Therapy Designation for relutrigine
select
Sign Up For More Events

News

9.5
08-04Newsfilter
PinnedPraxis Precision Medicines, Inc. (PRAX) Q2 2025 Earnings Call Transcript
9.0
08-04Benzinga
PinnedPraxis' Epilepsy Treatment Shows Promise With Decreased Seizures
7.0
08-06PRnewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Praxis Precision Medicines, Inc. - PRAX
Sign Up For More News

FAQ

arrow icon

What is Praxis Precision Medicines Inc (PRAX) stock price today?

The current price of PRAX is 48.6 USD — it has increased 1.69 % in the last trading day.

arrow icon

What is Praxis Precision Medicines Inc (PRAX)'s business?

arrow icon

What is the price predicton of PRAX Stock?

arrow icon

What is Praxis Precision Medicines Inc (PRAX)'s revenue for the last quarter?

arrow icon

What is Praxis Precision Medicines Inc (PRAX)'s earnings per share (EPS) for the last quarter?

arrow icon

What changes have occurred in the market's expectations for Praxis Precision Medicines Inc (PRAX)'s fundamentals?

arrow icon

How many employees does Praxis Precision Medicines Inc (PRAX). have?

arrow icon

What is Praxis Precision Medicines Inc (PRAX) market cap?